African Swine Fever (ASF) is a highly lethal viral disease in swine, causing near 100% mortality. Extensive efforts have been made to develop effective ASF vaccines, with live-attenuated virus (LAV) vaccines produced by deleting virulence genes from virulent African Swine Fever Virus (ASFV) strains showing promising safety and efficacy. This article reviews recent progress in developing and characterizing gene-deleted LAV vaccine candidates. Virulence genes targeted for deletion can be categorized into four groups: genes involved in viral genome replication and transcription, genes from the multigene family (MGF), genes involved in hemadsorption and cellular attachment, and novel genes with unknown functions. Several gene-deleted LAV vaccine candidates have been generated, with varying degrees of attenuation and protective efficacy in pigs. Some candidates, such as those deleting MGF genes, CD2v, and I177L, have shown promising results. However, the effects of gene deletions can vary depending on the ASFV strain used, and reversion to virulence has been observed in some cases. The article also discusses the challenges and future directions in developing effective ASF vaccines, including the need for stable cell lines for vaccine production and the evaluation of DIVA markers.African Swine Fever (ASF) is a highly lethal viral disease in swine, causing near 100% mortality. Extensive efforts have been made to develop effective ASF vaccines, with live-attenuated virus (LAV) vaccines produced by deleting virulence genes from virulent African Swine Fever Virus (ASFV) strains showing promising safety and efficacy. This article reviews recent progress in developing and characterizing gene-deleted LAV vaccine candidates. Virulence genes targeted for deletion can be categorized into four groups: genes involved in viral genome replication and transcription, genes from the multigene family (MGF), genes involved in hemadsorption and cellular attachment, and novel genes with unknown functions. Several gene-deleted LAV vaccine candidates have been generated, with varying degrees of attenuation and protective efficacy in pigs. Some candidates, such as those deleting MGF genes, CD2v, and I177L, have shown promising results. However, the effects of gene deletions can vary depending on the ASFV strain used, and reversion to virulence has been observed in some cases. The article also discusses the challenges and future directions in developing effective ASF vaccines, including the need for stable cell lines for vaccine production and the evaluation of DIVA markers.